BridgeBio LLC

67 articles with BridgeBio LLC

• BridgeBio Pharma Reported Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  1/6/2021

  BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on January 4, 2021, the compensation committee of BridgeBio’s board of directors granted six new employees restricted stock units for an aggregate of 4,126 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan). The above-descr

• UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases

  12/23/2020

  UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients. “The BridgeBio team is developing close relationships with our investigators at UCSF with the mission of bringing potential therapies into the clinic quickly, where they have the opportunity to help patients in need,” said Barry

• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Dec 04, 2020

  12/4/2020

  BridgeBio Pharma, Inc. announced that on December 1, 2020, the compensation committee of BridgeBio’s board of directors granted 15 new employees options to purchase an aggregate of 15,351 shares of the Company’s common stock with a per share exercise price of $51.13 and restricted stock units for an aggregate of 21,092 shares of the Company’s common stock.

• BridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations

  11/13/2020

  BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Navire Pharma, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of its SHP2 inhibitor (BBP-398) in patients with solid tumors driven by mutations in the MAPK signaling pathway, including RAS and receptor tyrosine kinase genes. BBP-398 was developed through a collaboration with The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery divis

• BridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business Update

  11/5/2020

  - Merger agreement executed between BridgeBio and Eidos Therapeutics; Potential to bring BridgeBio’s clinical and commercial development infrastructure to bear upon Eidos’ Acoramidis  - New Drug Application f or Fosdenopterin f or t he t reatment o f MoCD Type A accepted by the FDA under Priority Review designation - I nitiated two new clinical trials since last quarterly update and progressed additional 1 5 ongoing clinical trials

• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Nov 04, 2020

  11/4/2020

  BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company focused on genetic diseases, announced that on November 1, 2020, the compensation committee of BridgeBio’s board of directors granted three new employees restricted stock units for an aggregate of 9,566 shares of the Company’s common stock.

• BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement

  10/5/2020

  Agreement Brings BridgeBio’s Clinical Development and Commercial Development Infrastructureto Bear Upon Eidos’Acoramidis, Creating Anticipated Value for Patients with ATTR and Investors

• 

  BridgeBio Acquires Remaining Stake in Eidos to Tune of $175 Million

  10/5/2020

  The transaction between BridgeBio and Eidos is expected to close in the first quarter of 2021.

• BridgeBio Pharma to Host Virtual R&D Day on September 29, 2020

  9/22/2020

  BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases and cancers with clear genetic drivers, today announced that it will host its first R&D Day on Tuesday, September 29, at 8:30 am E.T. The virtual event will feature presentations from BridgeBio founder and CEO, Neil Kumar, Ph.D., senior scientists and physicians leading BridgeBio's drug discovery and development programs, and

• BridgeBio Pharma’s Calcilytix Therapeutics Initiates Phase 2 Study Of Encaleret For Autosomal Dominant Hypocalcemia Type 1 (ADH1)

  9/21/2020

  BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Calcilytix Therapeutics, Inc. announced today the initiation of a Phase 2 single-center study of encaleret (CLTX-305) in individuals with ADH1 conducted at the National Institutes of Health. ADH1 is a rare, inherited disease caused by gain-of-function mutations in the c

• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Sep 03, 2020

  9/3/2020

  BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company focused on genetic diseases, announced that on September 1, 2020, the compensation committee of BridgeBio’s board of directors granted 10 new employees options to purchase an aggregate of 18,231 shares of the Company’s common stock with a per share exercise price of $27.62 and restricted stock units for an aggregate of 19,915 shares of the Company’s common stock.

• BridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results and Business Update

  8/11/2020

  -Initiated four clinical trials, progressed its additional 11 ongoing clinical trials and submitted three INDs to FDA since the beginning of 2020 -Strategic collaboration with Perceptive Advisors-founded company LianBio expands BridgeBio’s global reach into China -Ended quarter with $840.9 million in cash, cash equivalents and marketable securities SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focu

• BridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio

  8/11/2020

  $26.5 million total near-term payments to BridgeBio, plus participation in long-term value creation of up to $505 million in milestone payments, tiered double-digit royalty payments and an equity interest in LianBio. BridgeBio CEO and founder Neil Kumar, Ph.D., has been appointed to LianBio’s board of directors. PALO ALTO, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases and cancers

• BridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia

  7/15/2020

  BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that the first child with achondroplasia has been dosed with the investigational medicine infigratinib, an orally available small molecule, that targets the overactivity of fibroblast growth factor receptor 3 (FGFR3) in the PROPEL 2 Phase 2 clinical trial . Achondroplasia is the most common cause of disproportionate short stature.¹ “With preclinical evidence sh

• BridgeBio Pharma’s Phoenix Tissue Repair to Highlight Interim Phase 1/2 Study Data in a Presentation at the Society for Pediatric Dermatology’s 45th Annual Meeting

  7/10/2020

  BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Phoenix Tissue Repair (PTR) today announced an upcoming presentation of interim data from an ongoing Phase 1/2 study of PTR-01 (BBP-589), an intravenously-administered recombinant collagen 7 protein replacement therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB). The presentation will be made during the Society for Pediatric Dermatology’s (SPD) 45th Annual Meeting, to be held virtu

• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 06, 2020

  7/6/2020

  BridgeBio Pharma, Inc. announced that on July 1, 2020, the compensation committee of BridgeBio’s board of directors granted eight employees options to purchase an aggregate of 7,120 shares of the Company’s common stock with a per share exercise price of $30.34 and restricted stock units for an aggregate of 15,134 shares of the Company’s common stock, including 1,610 performance-related restricted stock units.

• 

  BioSpace Movers & Shakers, June 26

  6/26/2020

  Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.

• BridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors

  6/24/2020

  BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it has added three new independent directors to its board: former Allergan CEO and biopharma deal-maker, Brent Saunders; genomics pioneer and entrepreneur, Randy Scott, Ph.D.; and renowned economist and BridgeBio co-founder, Andrew Lo, Ph.D. “We are privileged to welcome these world-class company builders, inn

• BridgeBio Pharma, Inc. Enters Into Collaboration Agreement With Johns Hopkins University to Accelerate Development of New Medicines in Genetically Driven Diseases

  6/18/2020

  BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it has entered into a collaboration agreement with Johns Hopkins University to support the translation of academic innovations in genetically driven diseases with a goal of clinical development and potential commercialization to reach patients in need. “We are privileged to establish a framework for collaborat

• BridgeBio Pharma and University of Florida Establish Collaboration to Advance Therapies for Genetically Driven Diseases

  6/18/2020

  Partnership to Leverage University of Florida’s Research in Gene Therapy and BridgeBio’s Translational Expertise in Rare and Genetic Disease